Journal of Clinical Oncology
Articles in this Issue
Temporal trends in cardiovascular and cerebrovascular mortality among U.S. decedents with malignant neoplasms of the bronchus and lung, 1999–2020.
e20110 Background: Lung cancer is associated with substantial cancer-specific mortality; however, cardiovascular diseases...
Predictive role of immune cell subsets and intestinal flora in immune-related adverse event of small cell lung cancer.
8112 Background: While immune checkpoint inhibitors (ICIs) have reshaped the therapeutic landscape for extensive-stage sma...
Hospitalized oncology patients with diarrhea: Clinical outcomes and prognostic factors.
11136 Background: Diarrhea is a frequent cause of hospitalization in oncology patients and may lead to substantial morbidi...
Vaccine-induced immune responses, HLA genotyping, and molecular profiling in patients with metastatic ovarian cancer (the PESCO trial).
5600 Background: PESCO, a phase 1/2 trial of Maveropepimut-S (MVP-S) in combination with Pembrolizumab and metronomic cycl...
Predictors of fibrotic progression in myeloproliferative neoplasms: A real-world retrospective cohort study.
e18607 Background: Progression to myelofibrosis (MF) is associated with worse survival and influences treatment decisions,...
Identifying cancer cachexia using clinical reasoning artificial intelligence (AI).
1613 Background: Cancer cachexia, a severe wasting syndrome, affects up to 87% of cancer patients 1...
Multimodal immunoprofiling of peripheral blood using foundation models of the immune system for predicting immunotherapy response and toxicity in the RADIOHEAD pan-cancer cohort.
2533 Background: While immune checkpoint inhibition (ICI) is an emerging gold standard for cancer therapy, positive respon...
Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma: Interim futility analysis.
7002 Background: The median age at diagnosis of diffuse large B-cell lymphoma (DLBCL) is approximately 65 years, with near...
Efficacy and safety of DR4/DR5 agonist aponermin monotherapy in advanced chondrosarcoma: Preliminary report from a prospective, multicenter study.
11532 Background: Reported median progression-free survival (mPFS) of Chondrosarcoma is less than 4 months for patients re...
Comparing becotarug plus osimertinib with a real-world osimertinib therapy cohort in platinum-refractory, advanced non–small cell lung cancer with EGFR exon 20 insertion.
8546 Background: EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is a rare subtype with limited...
Clinical utility of whole transcriptome sequencing for fusion detection in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2.
3127 Background: Fusion variants represent established therapeutic targets in precision oncology yet are incompletely capt...
Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.
7500 Background: Early intervention with lenalidomide or daratumumab significantly delays disease progression to a...
Does the global cancer research funding by public and philanthropic investments address important research gaps?
e23032 Background: Public and philanthropic funding are vital to all domains of cancer research, yet little is known about...
Antibody-drug conjugate plus immunotherapy versus chemotherapy-immunotherapy in PD-L1–positive metastatic triple-negative breast cancer: A trial-anchored analysis.
e13122 Background: Pembrolizumab plus chemotherapy is an established first-line for unresectable locally advanced or metas...
Enhancing communication about cancer management and cancer care delivery for older adults with dementia and their care partners.
TPS12166 Background: Dementia affects 7–10% of older adults with cancer and is associated with worse cancer outcomes. Many...
The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis.
11000 Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed in patients wi...
National trends in palliative care use among hospitalized cancer patients: A seven-year analysis of demographic and socioeconomic disparities.
12073 Background: The 2016 ASCO guidelines recommend that patients with advanced cancer receive dedicated palliative care...
Comprehensive molecular and clinical characterization of early-onset gastrointestinal cancers: Integrating genomic landscapes with allostatic load in a safety-net cohort.
e22621 Background: The incidence of early-onset gastrointestinal cancers (EOGIC), diagnosed in individuals underage 50, is...
Supportive care gaps during breast cancer treatment in Vietnam: Determinants and quality-of-life correlates in a resource-constrained setting.
e12733 Background: In low- and middle-income countries (LMICs), breast cancer outcomes are increasingly shaped not only by...
The role of pretreatment vitamin D insufficiency in racial disparity in taxane-induced peripheral neuropathy: Results from the SWOG S0221 trial.
12136 Background: Taxane-induced peripheral neuropathy (TIPN) affects up to 70% of patients receiving taxanes and can lead...
A new era of immunotherapy: Comparison of real-world outcomes in limited-stage small cell lung cancer.
e20141 Background: Concurrent chemoradiation (CCRT) followed by consolidative anti-PD-L1 immunotherapy (IO) with durvaluma...
Factors associated with early cachexia in metastatic NSCLC: A nationwide Veterans Health Administration analysis.
e20681 Background: Cancer-associated cachexia is a frequent and often irreversible driver of morbidity in non-small cell l...
Inpatient outcomes and resource utilization by complication clustering phenotypes among colorectal cancer hospitalizations in the United States.
e23215 Background: Acute complications are common drivers of hospitalization in colorectal cancer (CRC), yet most inpatien...
A first-in-human (FIH), phase I/II open-label, dose-escalation and -expansion study of ILKN421H, an LNP mRNA encoding an IL2Rβγ selective IL-2v, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.
8556 Background: ILKN421H is an LNP mRNA encoding an IL2Rβγ selective IL-2v derivative fused with Human Serum Album. Precl...
Longitudinal genomic characterization of pediatric acute myeloid leukemia at diagnosis and relapse.
10020 Background: Relapse remains the leading cause of treatment failure and mortality in pediatric acute myeloid leukemia...